Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Eur J Neurol. 2021 Apr;28(4):1316-1323. doi: 10.1111/ene.14632. Epub 2020 Dec 3.
SMART (stroke-like migraine attacks after radiation therapy) is a rare, delayed complication of brain radiation. In this study, we wanted to review the spectrum of symptoms, neuroradiological findings, autoimmune status, and outcomes in SMART syndrome patients.
We conducted a retrospective cohort study of all consecutive adult patients (≥18 years) diagnosed with SMART syndrome at Mayo Clinic, Rochester between January 1995 and December 2018.
We identified 25 unique patients with SMART syndrome and a total of 31 episodes and 15 (60%) patients were male. The median age at onset was 46 (interquartile range [IQR] 43-55) years and the median latency of onset after the initial radiation was 21.6 (IQR 14.4-28.2) years. Magnetic resonance imaging (MRI) showed gyral edema and enhancement in all cases with the temporal (25, 80.6%) and parietal (23, 74.2%) lobes being the most commonly affected. The median follow-up of the patients in our cohort was 10 (IQR 6-32) weeks. On univariate analysis, factors associated with an increased risk of recurrent SMART episodes were female gender (odds ratio [OR] 8.1, 95% confidence interval [95% CI] 1.1-52.6, p = 0.019) and absence of electrographic seizure discharges during initial symptoms (OR 7.4, 95% CI 1.1-45.9, p = 0.032). We could not identify an autoimmune etiology. Longer duration of symptoms (>10 weeks) correlated with an older age (p = 0.049), temporal lobe involvement (p < 0.001), and diffusion restriction (p = 0.043).
SMART is a syndrome with characteristic imaging findings and clinical features. Incomplete recovery by 10 weeks occurred in one-third of individuals and was associated with older age, temporal lobe involvement, and restricted diffusion on MRI.
SMART(放疗后类似中风的偏头痛发作)是一种罕见的、延迟性的脑放疗并发症。本研究旨在回顾 SMART 综合征患者的症状谱、神经影像学表现、自身免疫状态和结局。
我们对 1995 年 1 月至 2018 年 12 月在 Mayo 诊所罗切斯特院区连续确诊的所有成人(≥18 岁) SMART 综合征患者进行了回顾性队列研究。
我们共发现 25 例 SMART 综合征患者,共 31 次发作,15 例(60%)患者为男性。发病年龄中位数为 46(四分位距 [IQR] 43-55)岁,初始放疗后发病潜伏期中位数为 21.6(IQR 14.4-28.2)年。磁共振成像(MRI)显示所有病例均有脑回水肿和增强,最常受累的部位是颞叶(25 例,80.6%)和顶叶(23 例,74.2%)。本队列患者的中位随访时间为 10(IQR 6-32)周。单因素分析显示,女性(比值比 [OR] 8.1,95%置信区间 [95%CI] 1.1-52.6,p=0.019)和初始症状期间无脑电图痫性放电(OR 7.4,95%CI 1.1-45.9,p=0.032)与 SMART 反复发作风险增加相关。我们未能确定自身免疫病因。症状持续时间较长(>10 周)与年龄较大(p=0.049)、颞叶受累(p<0.001)和弥散受限(p=0.043)相关。
SMART 是一种具有特征性影像学表现和临床特征的综合征。10 周内未完全恢复的情况发生在三分之一的个体中,与年龄较大、颞叶受累和 MRI 上的弥散受限相关。